CLINICAL TRIALS PROFILE FOR TRISENOX
✉ Email this page to a colleague
505(b)(2) Clinical Trials for Trisenox
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Dosage | NCT00225992 ↗ | Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS) | Terminated | Oncology Specialties, Alabama | Phase 2 | 2004-02-01 | In this phase II study besides evaluating for safety, the primary efficacy parameter is to evaluate the incidence of patients who have had a response to Trisenox by evidence of increased blood counts (red, white, or platelets) and/or by decrease or transfusion dependency. The secondary efficacy parameter is the assessment of the tolerability of the new dosing schedule. Arsenic trioxide will be administered intravenously over 1 to 2 hours with a loading dose of 0.30mg/kg for days 1-5 of the first week and then twice weekly for 27 weeks for a total of 28 weeks. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for Trisenox
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00003934 ↗ | Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia | Completed | National Cancer Institute (NCI) | Phase 3 | 1999-06-01 | This randomized phase III trial is studying tretinoin and combination chemotherapy to see how well they work compared to tretinoin, combination chemotherapy, and arsenic trioxide in treating patients with acute promyelocytic leukemia that has not been treated previously. Drugs used in chemotherapy, such as daunorubicin, cytarabine, mercaptopurine, methotrexate, and arsenic trioxide, work in different ways to stop cancer cells from dividing so they stop growing or die. Tretinoin may help leukemia cells develop into normal white blood cells. It is not yet known which regimen is more effective for acute promyelocytic leukemia. |
| NCT00005786 ↗ | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia | Terminated | National Cancer Institute (NCI) | N/A | 2001-01-01 | Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have relapsed or refractory lymphoma or leukemia. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die |
| NCT00006092 ↗ | Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia | Terminated | National Cancer Institute (NCI) | Phase 2 | 2000-08-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have recurrent or refractory acute lymphoblastic leukemia or chronic myelogenous leukemia. |
| NCT00006092 ↗ | Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia | Terminated | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | 2000-08-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have recurrent or refractory acute lymphoblastic leukemia or chronic myelogenous leukemia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Trisenox
Condition Name
Clinical Trial Locations for Trisenox
Trials by Country
Clinical Trial Progress for Trisenox
Clinical Trial Phase
Clinical Trial Sponsors for Trisenox
Sponsor Name
